MedTrace Logo

An Open Label Trial of TMS Therapy for Bipolar Depression

NCT02640950 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-06-01

Study results available
· View outcomes & findings →

Summary

Transcranial Magnetic Stimulation (TMS) is an increasingly accepted neurostimulation- based treatment for major depressive disorder. While there is a growing anecdotal database supporting its use in bipolar depression the investigators propose to collect open label efficacy and safety data in a small population of patients with clinically verified bipolar disorder.

Conditions

Interventions

DEVICE

NeuroStar TMS

Transcranial Magnetic Stimulation

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • Sheppard Pratt Health System

    lead OTHER

Principal Investigators

  • Scott T Aaronson, MD · Sheppard Pratt Health System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02640950 on ClinicalTrials.gov